Monitoring molecular response in chronic myeloid leukemia

Cancer

Volumn 117, Issue 6, 2011, Pages 1113-1122

  Cortes, Jorge ^a   Quintás Cardama, Alfonso ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BCR ABL; chronic myeloid leukemia; imatinib; molecular response; tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PROTEIN BCR ABL1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

BCR ABL1 GENE; CANCER GROWTH; CANCER RELAPSE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG RESPONSE; EVENT FREE SURVIVAL; GENETIC TRANSCRIPTION; HEMATOLOGICAL PARAMETERS; HUMAN; MOLECULAR RESPONSE; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CYTOGENETIC ANALYSIS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; MONITORING, PHYSIOLOGIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952381341     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25527     Document Type: Review

References (40)

1. Quintas-Cardama A, Cortes J., Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113: 1619-1630.
2. Ren R., Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5: 172-183. (Pubitemid 40314949)
3. Van Etten RA., Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004; 28 (suppl 1): S21-S28. (Pubitemid 38251495)
4. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA., JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004; 18: 189-218. (Pubitemid 38240034)
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004. (Pubitemid 36302244)
6. Kantarjian HM, Giles FJ, Bhalla KN, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood. 2009; 114: 464.
7. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95: 232-240.
8. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009; 114: 462.
9. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 1809-1820. (Pubitemid 44394987)
10. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27: 6041-6051.
11. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003; 97: 1033-1041. (Pubitemid 36173155)
12. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M., Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. the leukemia service. Ann Intern Med. 1995; 122: 254-261.
13. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions ? Cancer. 2008; 112: 837-845. (Pubitemid 351240578)
14. Branford S, Hughes TP, Rudzki Z., Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999; 107: 587-599.
15. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM., Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993; 82: 1929-1936. (Pubitemid 23278786)
16. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112: 3330-3338.
17. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37. (Pubitemid 43990609)
18. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 1423-1432. (Pubitemid 37211057)
19. Ross DM, Branford S, Moore S, Hughes TP., Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by real-time QPCR for BCR-ABL. Leukemia. 2006; 20: 664-670.
20. Guilhot F, Larson RA, O'Brien SG, Gathmann I, Druker BJ,. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy [abstract]. Blood. 2007; 110: 16a.
21. Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003; 17: 1687-1694. (Pubitemid 37185241)
22. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11: 3425-3432. (Pubitemid 40627896)
23. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006; 12: 3037-3042. (Pubitemid 43837348)
24. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112: 4437-4444.
25. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007; 13: 6136-6143. (Pubitemid 350075073)
26. Hughes TP, Hochhaus A, Branford S, et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) [abstract]. Blood. 2008; 112: 129-130.
27. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006; 107: 4250-4256. (Pubitemid 43801348)
28. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26: 3358-3363.
29. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003; 17: 2401-2409. (Pubitemid 38072578)
30. Muller MC, Hanfstein B, Erben P, et al. Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia: an interim analysis of the randomized German CML study IV [abstract]. Blood. 2008; 112: 129.
31. Wang L, Pearson K, Ferguson JE, Clark RE., The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003; 120: 990-999. (Pubitemid 36411558)
32. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009; 113: 6315-6321.
33. Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009; 27: 3659-3663.
34. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial [abstract]. Blood. 2009; 114. Abstract #LBA-1.
35. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood. 2009; 114: 144.
36. Cortes J, Borthakur G, O'Brien S, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood. 2009; 114: 143.
37. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109: 58-60. (Pubitemid 46053043)
38. Goh HG, Kim YJ, Kim DW, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma. 2009; 50: 944-951.
39. Cortes J, O'Brien S, Kantarjian H., Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 104: 2204-2205. (Pubitemid 39297882)
40. Mahon FX, Rea D, Guilhot F, et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients [abstract]. Blood. 2009; 114: 353.